JACC: CASE REPORTS © 2022 THE AUTHORS. PUBLISHED BY ELSEVIER ON BEHALF OF THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION. THIS IS AN OPEN ACCESS ARTICLE UNDER THE CC BY-NC-ND LICENSE (http://creativecommons.org/licenses/by-nc-nd/4.0/).

CASE REPORT

ADVANCED

CLINICAL CASE: IMAGING AND GENERAL CARDIOLOGY

Embolized Hydrophilic Coating Polymers Found in Left Ventricular Assist Device Apical Core Specimen

Nir Levi, MD,^a Ehud Jacobzon, MD,^b Anna Tobar, MD,^c Tatyana Weitsman, MD,^a Joseph J. Maleszewski, MD,^{d,e} Tal Hasin, MD^a

ABSTRACT

Left ventricular assist devices are increasingly used in patients with advanced heart failure. Gross and histologic evaluation of myocardial apical core specimens, extracted during device placement, can provide important insights. Herein, we describe a case of hydrophilic polymer embolization with associated foreign-body giant cell reaction discovered during apical core evaluation. (**Level of Difficulty: Advanced**.) (J Am Coll Cardiol Case Rep 2022;4:819–821) © 2022 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an

open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

HISTORY OF PRESENTATION

A 59-year-old woman with ischemic cardiomyopathy and left ventricular ejection fraction of 30% was admitted to the cardiology department to evaluate for left ventricular assist device (LVAD) implantation in the setting of worsening heart failure. On admission, her vital signs were normal and her physical

LEARNING OBJECTIVES

- To understand the importance of examining apical core specimens in patients undergoing LVAD implantation.
- To recognize the possible complication of embolization of hydrophilic polymer coating during catheter-based coronary interventions causing a foreign-body giant cell reaction.

examination revealed elevated jugular venous pressure and mild bibasilar crackles. After a comprehensive assessment, the patient underwent LVAD (HeartMate 3, Abbott Laboratories) implantation surgery with an uneventful course. Routine histopathologic examination of the apical core specimen, extracted during device placement, was performed and revealed multifocal nonnecrotizing granulomas.

PAST MEDICAL HISTORY

Past medical history included type 2 diabetes mellitus and ischemic heart disease (IHD). Six years before the current admission she presented with ST-segment elevation myocardial infarction causing cardiogenic shock and she underwent percutaneous coronary intervention (PCI) with drug-eluting stents (DES) deployed in a wraparound left anterior descending (LAD) and left circumflex arteries. Because of recurrent

Manuscript received February 22, 2022; revised manuscript received March 9, 2022, accepted March 21, 2022.

From the ^aJesselson Integrated Heart Center, Shaare Zedek Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel; ^bDepartment of Cardiothoracic Surgery, Shaare Zedek Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel; ^cDepartment of Pathology, Rabin Medical Center, Petah Tikva, Israel; ^dDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA; and the ^eDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.

The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center.

ABBREVIATIONS AND ACRONYMS

DES = drug-eluting stent(s)

IHD = ischemic heart disease

LAD = left anterior descending artery

LVAD = left ventricular assist device

PCI = percutaneous coronary intervention

chest pain, 2 additional PCIs with DESs to the LAD and diagonal branch were performed.

DIFFERENTIAL DIAGNOSIS

The differential diagnosis of granulomas in myocardial biopsy includes giant cell myocarditis, sarcoidosis, infectious diseases, and foreign-body giant cell reaction.¹

INVESTIGATIONS

Histopathologic examination disclosed numerous granulomas surrounding a nonpolarizable basophilic foreign material (Figure 1). The granulomas contained CD68-reactive giant cells and were negative for periodic acid-Schiff and Ziehl-Neelsen stains. A Masson trichrome stain exhibited marked interstitial fibrosis and perivascular fibrosis. The morphology of the foreign material was diagnostic of hydrophilic polymer, thought to be a result of an earlier PCI (eg, coronary guidewires, introducer, or delivery sheaths).

DISCUSSION

Apical tissue, extracted during LVAD implantation, can reveal undiagnosed cardiac pathologies and can

provide important insights into pathophysiology and prognosis, and may even help to dictate therapy. For instance, Schultz et al² showed that in apical core samples obtained during LVAD implantation, patients with IHD had more myocardial fibrosis than patients with nonischemic cardiomyopathy, and that myocardial fibrosis was more common in older patients and those with an implantable cardiac defibrillator. In another study, interstitial fibrosis was shown to be inversely related to survival and functional improvement, suggesting that quantification of myocardial fibrosis is a possible marker for prognosis in this group of patients.³ In addition, uncommon histopathologic findings in apical core samples have been reported^{4,5}; however, to the best of our knowledge, this is the first report to demonstrate hydrophilic polymer embolization in this specimen type.

Embolization of hydrophilic coating polymers is an increasingly recognized complication of endovascular catheter-based procedures. This complication was previously described in multiple procedures and tissues, most commonly in the brain in patients who underwent neurointerventional procedures, but also in the lungs, kidneys, and lower extremities, and even as a cause of valve thrombosis after



Photomicrograph of the apical core specimen showing scattered nonnecrotizing granulomas with foreign-body giant cells surrounding embolized hydrophilic polymer (arrows) (hematoxylin and eosin staining; A, ×40; B and C, ×400). (D) Immunohistochemical staining of giant cells with CD68-reactive macrophages (×100).

transcatheter aortic valve replacement.^{6,7} This phenomenon was previously described also as a rare complication of cardiac catheterizations and PCI where shearing and embolization of hydrophilic polymer coating from coronary guidewires, introducer, or delivery sheaths were demonstrated. Although the true incidence of this complication is unknown, it is thought to be highly underestimated, possibly because of the need of histopathologic tissue examination for diagnosis confirmation. In a study by Grundeken et al,⁸ hydrophilic coating polymers were demonstrated in almost one-half of coronary thrombus aspirates and in 10% of autopsies of patients who underwent PCI, with variability that depends on the guidewire used. The embolization of hydrophilic polymers during endovascular coronary interventions might result in a tissue reaction, characterized by foreign-body granulomas; however, tissue reaction is time dependent as granulomas and fibrosis develop on the long term and short term observations showed only minimal inflammatory response with no giant cell reaction.8,9 The embolization of hydrophilic polymers has been reported to be associated with different cardiac (eg, stent thrombosis, aortic valve thrombosis, and myocardial ischemia) and noncardiac (eg, stroke, cerebral edema, glomerular ischemia, pulmonary infarction, and livedo reticularis) clinical sequelae.⁶⁻⁹ Therefore, in November 2015 the U.S. Food and Drug Administration issued a safety communication to inform health care providers about the risk of hydrophilic coating embolization and the potential of adverse events.¹⁰ Currently, there are no studies to evaluate the

clinical significance or prognostic implications of this phenomenon, and they are yet to be assessed in future studies. Moreover, it is not yet clear if this finding portends prognostic significance in the setting of LVAD placement.

FOLLOW-UP

The patient significantly improved her functional status while on LVAD support, suggesting that this finding may be incidental.

CONCLUSIONS

This case highlights the importance of histopathologic examination of the apical core samples extracted during LVAD implantations. Such evaluation can demonstrate surprising findings and provide invaluable insights. In addition, it emphasizes the importance of clinicopathologic correlation and brings to attention the possibility of embolization of hydrophilic coating polymers to the myocardium, causing a foreign-body giant cell reaction, a potentially underrecognized complication of cardiac catheterizations and PCI.

FUNDING SUPPORT AND AUTHOR DISCLOSURES

The authors have reported that they have no relationships relevant to the contents of this paper to disclose.

ADDRESS FOR CORRESPONDENCE: Dr Tal Hasin, Jesselson Integrated Heart Center, Shaare Zedek Medical Center, 12 Shmuel Beit Street, Jerusalem 9103102, Israel. E-mail: hasintal@gmail.com.

REFERENCES

1. Cooper LT. Giant cell myocarditis: diagnosis and treatment. *Herz.* 2000;25:291–298.

2. Schultz J, John R, Martin C, Kamdar F, Thenappan T, Cogswell R. Prevalence of myocardial fibrosis by left ventricular assist device apical core biopsy and correlation with other markers of myocardial recovery. *ASAIO J.* 2019;65:123-126.

3. Bruckner BA, Razeghi P, Stetson S, et al. Degree of cardiac fibrosis and hypertrophy at time of implantation predicts myocardial improvement during left ventricular assist device support. *J Heart Lung Transplant*. 2004;23:36-42.

4. Ryugo M, Izutani H, Okamura T, et al. Cardiac sarcoidosis diagnosed by histological assessment of a left ventricular apical core excised for insertion of a left ventricular assist device. *Gen Thorac Cardiovasc Surg.* 2013;61:716–718.

5. Philipsen TE, Vermeulen T, Conraads VM, Rodrigus IE. Disseminated malignancy after extracorporeal life support and left ventricular assist device, diagnosed by left ventricular apical core biopsy. *Interact Cardiovasc Thorac Surg*. 2013;17:875-877.

6. Kitamura T, Oishi H, Fujii T, et al. Delayed complications due to polymer coating embolism after endovascular treatment. *NMC Case Rep J*. 2020;7:5-10.

7. Sanon S, Maleszewski JJ, Rihal CS. Hydrophilic polymer embolism induced acute transcatheter aortic valve thrombosis: a novel complication. *Catheter Cardiovasc Interv.* 2014;83:1152–1155.

8. Grundeken MJ, Li X, Kurpershoek CE, et al. Distal embolization of hydrophilic-coating material from coronary guidewires after percutaneous coronary interventions. *Circ Cardiovasc Interv*. 2015;8:e001816.

9. Chopra AM, Mehta M, Bismuth J, et al. Polymer coating embolism from intravascular medical devices—a clinical literature review. *Cardiovasc Pathol.* 2017;30:45–54.

10. U.S. Food and Drug Administration. Lubricious coating separation from intravascular medical devices: FDA safety communication. Accessed February 18, 2022. http://wayback.archive-it. org/7993/20161022044037/. https://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm473794.htm

KEY WORDS giant cell, ischemic heart disease, left ventricular assist device, percutaneous coronary intervention